Physician profile
Ran Atzmon
NPI 1558023267
$37,699.11
in general payments reported to CMS, 2019-2025
6 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $14K · 2022: $23K.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $21,250.00 | 2021-2022 | |
| Evolution Surgical, INC | $11,126.29 | 2021-2022 | |
| Arthrex, INC. | $4,796.85 | 2022 | |
| Stryker Corporation | $292.54 | 2021-2022 | |
| Xiros INC | $130.49 | 2022 | |
| Exactech, INC. | $102.94 | 2022 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ran Atzmon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.